Bankruptcy Administration Improvement Act of 2025

The Bankruptcy Administration Improvement Act of 2025, enacted on February 6, 2026, amends titles 11 and 28 of the US Code. It modifies compensation for chapter 7 bankruptcy trustees and extends the term of temporary bankruptcy judge offices.

Ending Improper Payments to Deceased People Act

Congress has enacted the Ending Improper Payments to Deceased People Act, Public Law 119-77, effective February 10, 2026. The Act amends the Social Security Act to improve coordination between federal and state agencies and the Do Not Pay working system to prevent improper payments to deceased individuals.

Semiquincentennial Congressional Time Capsule Act Enacted

Congress has enacted the Semiquincentennial Congressional Time Capsule Act, establishing a time capsule to commemorate the United States' semiquincentennial. The Architect of the Capitol is tasked with its creation, with contents to be determined by congressional leadership.

Congress Disapproves D.C. Tax Conformity Act

The US Congress has disapproved the D.C. Income and Franchise Tax Conformity and Revision Temporary Amendment Act of 2025. This joint resolution, passed by both the House and Senate, nullifies the action taken by the District of Columbia Council.

FDA Warning Letter to MedisourceRx

The FDA issued a warning letter to MedisourceRx on December 12, 2025, for failing to meet the conditions of section 503B of the FDCA. The inspection revealed that the outsourcing facility did not submit adverse event reports as required, violating federal drug laws.

FDA Warning Letter to East CK Trading Inc.

The FDA issued a warning letter to East CK Trading Inc. for significant violations of the Foreign Supplier Verification Program (FSVP) regulation. The company failed to develop and maintain an FSVP for imported foods, leading to potential refusal of admission and detention without physical examination.

FDA Warning Letter to Dynamic Stem Cell Therapy

The FDA issued a warning letter to Dynamic Stem Cell Therapy for misbranding an umbilical cord-derived stem cell product. The product is considered an unapproved new drug and an unlicensed biological product, violating the Federal Food, Drug, and Cosmetic Act. The FDA's review found claims on the company's website indicating the product is intended to diagnose, cure, mitigate, treat, or prevent disease.

FDA Warning Letter to AQ USA Inc. for Drug Manufacturing Violations

The FDA issued a warning letter to AQ USA Inc., d.b.a Ross Healthcare Inc., for significant Current Good Manufacturing Practice (CGMP) violations at its drug manufacturing facility in Lynden, Washington. The violations include inadequate laboratory testing for microbial contamination and failure to establish appropriate specifications for drug products.

FDA Warning Letter to A. Nelson & Co. Ltd

The FDA issued a warning letter to A. Nelson & Co. Ltd. for significant violations of Current Good Manufacturing Practice (CGMP) regulations, including inadequate microbial testing and unsupported expiration date extensions. The company's drug products were found to be adulterated.

HHS OIG: Sarasota Memorial Hospital Medicare Overpayments Total $12.1 Million

The HHS Office of Inspector General (OIG) found that Sarasota Memorial Hospital received at least $12.1 million in Medicare overpayments between January 1, 2020, and December 31, 2021. The OIG recommended the hospital refund the overpaid amount and implement additional training.